Fig. 9

Comparisons of drug sensitivities among the TIDE subtypes of BC. A Submap analysis reflects the sensitivity of the TIDE subtypes to the targeted treatments in the BC patients. B–O Comparisons of the clinically preferred and recommended drugs sensitivity among BC TIDE subtypes: methotrexate (B), gemcitabine (C), pemetrexed (D), vincristine (E), paclitaxel (F), doxorubicin (G), bleomycin (H), cisplatin (I), erlotinib (J), AZD4547 (K), gefitinib (L), olaparib (M), imatinib (N), and cetuximab (O). P, Q Transcription levels of HER-2 (ERBB2) among the TIDE subtypes from TCGA-BLCA (P) and LY Dataset (Q). R IHC images of HER-2 from the real-world BC samples and analysis of HER-2 positive cells among the TIDE subtypes. Scale bar, 100 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance